Engineering antibodies that bind irreversibly

Details Engineering antibodies that bind irreversibly Engineering antibodies that bind irreversibly

2006-10-10

2006-10-10

Helms, Larry R. (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugated via claimed linking group, bond, chelating agent,...

C424S001110, C424S001110, C424S001530, C424S001650, C424S001690, C530S387100, C530S387300, C530S388100, C530S388800

Reexamination Certificate

active

07118745

ABSTRACT:
The present invention provides a mutant antibody comprising a reactive site not present in the wild-type of the antibody and a complementarity-determining region that specifically binds to a metal chelate, wherein the reactive site is in a position proximate to or within the complementarity-determining region.

REFERENCES:
patent: 4678667 (1987-07-01), Meares et al.
patent: 4722892 (1988-02-01), Meares et al.
patent: 5541287 (1996-07-01), Yau et al.
patent: 5747654 (1998-05-01), Pastan et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5837242 (1998-11-01), Holliger et al.
patent: WO 95/15979 (1995-06-01), None
Paul., Fundamental Immunology Raven Press, NY, chapter 8, p. 242, 1993.
Rudikoff et al., Proc. Natl. Acad. Sci. USA 79:1979-83, 1982.
Orlandi et al., Proc. Natl. Acad. Sci. USA 86:3833-3837, 1989.
M. Chinol, et al., “Biodistribution in tomour-bearing mice of two90Y-labelled biotins using three-step tumour targeting,”Nuclear Medicine Comm., 18:176-182 (1997).
David A. Goodwin, et al., “Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens,”J. Nucl. Med., 29:226-234 (1998).
David A. Goodwin, et al., “Pretargeted immunodcinigraphy: Effect of hapten valency on murine tumor uptake,”J Nucl. Med., 33:2006-2013 (1992).
D. J. Hnatowich, et al., “Investigations of avidin and biotin for imaging applications,”J. Nucl. Med., 28:1294-1302 (1987).
H. P. Kalofonos, et al., “Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antobodies: Preliminary communication,”J. Nucl. Med., 31:1791-1796 (1990).
Alexander l. Klinaov, et al., “Blood clearance of radiolabeled antibody: Enhancement by lactosamination and treatment with biotin-avidin or anti-mouse IgG antibodies,”J. Nucl. Med., 29:1951-1956 (1988).
J. Ian Marsh, et al., “Streptavidin and biotin as potential tumor imaging agents,”J. Nucl. Med., 29(5):728-729 (1988).
Damon L. Meyer, et al., “Kinetics of the dissociation of indium-(p-substituted-benzyl)ethylenediaminetetraacetic acid hapten analogues from the monoclonal anti-hapten antibody CHA255,”Bioconjuagate Chem., 1:278-284 (199).
Jeffrey T. Owens, et al., “Mapping the promoter DNA sites proximal to conserved regions of σ70in anEscherichia coliRNA polymerase-lacUV5 open promoter complex,”Biochemistry, 37:7670-7675 (1998).
Jeffrey T. Owens, et al., “Mapping the σ70subunit contact sites onEscherichia coliRNA polymerase with a σ70-conjugated chemical protease,”Proc. Natl. Acad. Sci. USA, 95:6021-6026 (1988).
G. Paganelli, et al., “Three-step monoclonal antibody tumor targeting in carcinoembyonic antigen-positive patients,”Cancer Research, 51:5960-5966 (1991).
G. Paganelli, et al., “Monoclonal antibody pretargetting techniques for tumour localization: the Avidin-biotin system,”Nuclear Medicine Comm., 12:211-234 (1991).
Dayton T. Reardan, et al., “Antibodies against metal chelates,”Nature, 316:265-268 (1985).
Bruno Robert, et al., Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor α1,Cancer research, 56:4758-4765 (1996).
Eric Rouvier, et al., “Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens,”Horm. Res., 47:163-167 (1997).
B. Schechter, et al., “Indirect immunotargeting of CIS-PT to human epidermoid carcinoma KB using the avidin-biotin system,”Int. J. Cancer, 48:167-172 (1991).
Vladimir V. Sinitsyn, et al., “Rapid blood clearance of biotinylated IgG after infusion of avidin,”J. Nucl. Med., 30:66-69 (1989).
Dwight R. Stickney, et al., “Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colarectal carcinoma,”Cancer Research, 51:6650-6655 (1991).
Fan Yuan, et al., “Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies,”Cancer Research, 51:3119-3130 (1991).

Affiliated with

Also associated with

Rating

Engineering antibodies that bind irreversibly does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Engineering antibodies that bind irreversibly, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Engineering antibodies that bind irreversibly will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3683620